Human gonadotrophin preparations patients can't afford new drugBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6931.788a (Published 19 March 1994) Cite this as: BMJ 1994;308:788
- S Lee,
- I A L Treharne
- Hale Clinic, London W1 Essex County Hospital, Colchester, Essex
- Ares -Serono Group, Geneva, Switzerland Serono Laboratories (UK), Welwyn Garden City, Herts AL7 1BG.
EDITOR, - Recently, a drug company launched a new gonadotrophin preparation and at the same time discontinued its previous product, which itself had been hailed as a major breakthrough on the basis that preparations containing low concentrations of luteinising hormone or follicle stimulating hormone alone were considered better at inducing ovulation. What concerns us is the sudden discontinuation of a product that many specialists had previously been encouraged to use. Though we believe in the advantage of preparations containing low luteinising hormone concentrations or follicle stimulating hormone alone,1,2 we are concerned for patients seeking treatment of infertility as many have to pay for their drugs.
We run a busy fertility clinic offering simple treatments such as superovulation with intrauterine insemination,3 transvaginal ultrasound monitored egg release and insemination (follicles are lanced to ensure ovulation), and direct oocyte transfer, a modification of gamete intrafallopian transfer (GIFT).*RF 3-5* These are …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial